Results 81 to 90 of about 247,670 (219)

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Blood Advances, 2020
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The purpose of our study was to identify factors
L. Vercellino, Roberta Di Blasi, S. Kanoun, B. Tessoulin, C. Rossi, M. D'aveni-Piney, L. Obéric, C. Bodet-Milin, P. Bories, P. Olivier, I. Lafon, A. Berriolo-Riedinger, E. Galli, S. Bernard, M. Rubio, C. Bossard, V. Meignin, P. Merlet, P. Feugier, S. le Gouill, L. Ysebaert, O. Casasnovas, M. Meignan, S. Chevret, C. Thieblemont   +24 more
semanticscholar   +1 more source

Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study [PDF]

, 2017
Background: Relapsed or refractory diffuse large B-cell and mantle-cell lymphoma have a poor prognosis. The EPOCH regimen and rituximab monotherapy have demonstrated activity as salvage therapies.
Betticher, D. C., Egli, F., Honegger, H. P., Jacky, E., Jermann, M., Jost, L. M., Kroner, Th, Stahel, R. A., Taverna, Ch   +8 more
core  

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply [PDF]

, 2017
n
Chiappella, Annalisa, Evangelista, Andrea, Martelli, Maurizio, Vitolo, Umberto   +3 more
core   +1 more source

Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment

American journal of hematology/oncology, 2019
Diffuse large B‐cell lymphoma (DLBCL) is the most common type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes that are differentially characterized by ...
Yang Liu, S. Barta
semanticscholar   +1 more source

Central nervous system intravascular lymphoma in a Malaysian. [PDF]

, 2011
Intravascular lymphoma (IVL) is a rare subtype of extranodal diffuse large cell lymphoma, characterized by intravascular proliferation of B or T lymphocytes within small blood vessels; which may lead to occlusive symptoms, its neurological involvement ...
Al-Edrus, Sharifah Aishah, Gan, Gin Gin, Ganesan, Dharmendra, Looi, Lai Meng, Mohamed Mukari, Shahizon Azura, Noordin, Mazin, Rahmat, Kartini, Ramli, Norlisah, Tan, Chong Tin   +8 more
core  

Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with mutation: A case report

SAGE Open Medical Case Reports
Despite advancements in the treatment of diffuse large B-cell lymphoma, including CAR T-cell therapy, TP53 mutations remain a significant negative prognostic factor in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ziyi Cai, Dongmei Zou, Qiang Ma, Wanling Sun, Yixian Guo   +4 more
doaj   +1 more source

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2)
Daisuke Ennishi, A. Jiang, M. Boyle, B. Collinge, B. Grande, S. Ben-Neriah, C. Rushton, Jeffrey Tang, N. Thomas, G. Slack, P. Farinha, K. Takata, T. Miyata-Takata, J. Craig, A. Mottok, B. Meissner, Saeed Saberi, Ali Bashashati, D. Villa, K. Savage, L. Sehn, R. Kridel, A. Mungall, M. Marra, Sohrab P. Shah, C. Steidl, J. Connors, R. Gascoyne, Ryan D. Morin, D. Scott   +29 more
semanticscholar   +1 more source

Regulation of molecular processes in diffuse large b-cell lymphoma [PDF]

, 2013
The molecular understanding of diseases has advanced rapidly due to the use of gene expression profiling. However, these methods have been hampered by the limitation to use frozen tissue specimens.
Högfeldt, Therese
core   +1 more source